Last reviewed · How we verify
Thalidomide Celgene™ — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Thalidomide Celgene™ (Thalidomide Celgene™) — Celgene.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Thalidomide Celgene™ TARGET | Thalidomide Celgene™ | Celgene | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Thalidomide Celgene™ CI watch — RSS
- Thalidomide Celgene™ CI watch — Atom
- Thalidomide Celgene™ CI watch — JSON
- Thalidomide Celgene™ alone — RSS
Cite this brief
Drug Landscape (2026). Thalidomide Celgene™ — Competitive Intelligence Brief. https://druglandscape.com/ci/thalidomide-celgene. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab